• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:张庆,侯连兵,陈凌云,许军,马安德,马云,程远雄.HPLC-MS/MS测定人血浆阿奇霉素浓度及生物等效性研究[J].中国现代应用药学,2010,27(2):148-151.
.Study on Determination of Azithromycin in Human Plasma by HPLC-MS/MS and Its Bioequivalent[J].Chin J Mod Appl Pharm(中国现代应用药学),2010,27(2):148-151.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2124次   下载 1848 本文二维码信息
码上扫一扫!
分享到: 微信 更多
HPLC-MS/MS测定人血浆阿奇霉素浓度及生物等效性研究
张庆,侯连兵,陈凌云,许军,马安德,马云,程远雄
作者单位
摘要:
目的 建立人血浆中阿奇霉素的高效液相色谱/质谱/质谱(HPLC-MS/MS)测定法,测定受试者口服阿奇霉素颗粒后的血药浓度,并对受试制剂与参比制剂的生物等效性进行评价。方法 19名健康受试者采用随机双交叉试验设计,单剂量口服阿奇霉素颗粒受试制剂和参比药物各500 mg,用HPLC-MS/MS测定用药后不同时间血药浓度。血药浓度-时间数据经DAS 2.0统计软件处理,计算主要药动学参数,并进行两种制剂的生物等效性评价。结果 受试制剂和参比制剂的Tmax分别为(2.5±1.1)h和(2.6±1.7)h,Cmax分别为(574.6±209.2) ng·mL-1和(594.5±229.9) ng·mL-1t1/2分别为(44.7±15.2) h和(42.0±13.0) h,AUC0-144分别为(5 319.6±2 507.8) h·ng·mL-1和(5 710.7±2 710.1)h·ng·mL-1,AUC0-∞分别为(5 704.2±2 858.7) h·ng·mL-1和(6 010.0±2 808.1) h·ng·mL-1, 以AUC0-144计算,相对生物利用度为(94.2±15.7)%。两制剂的主要药动学参数无显著性差异。结论 受试制剂与参比药物生物等效。
关键词:  阿奇霉素颗粒  药动学  生物等效性  HPLC-MS/MS
DOI:
分类号:
基金项目:
Study on Determination of Azithromycin in Human Plasma by HPLC-MS/MS and Its Bioequivalent
ZHANG Qinga  HOU Lianbinga  CHEN Lingyunb  XU Juna  MA Andeb  MA Yuna  CHEN Yuanxiongc
Abstract:
OBJECTIVE To develop an HPLC-MS/MS assay for determination of azithromycin in human plasma and to investigate the pharmacokinetics and bioequivalence of azithromycin granules in healthy volunteers. METHODS Ninteen volunteers were randomly divided into two groups (test and reference), with double cross over design, a single oral dose of 500 mg of test and reference azithromycin granules was administered to each volunteer. The concentration of azithromycin in plasma was determined by HPLC-MS/MS and pharmacokinetic parameters were calculated by DAS 2.0 practical pharmacokinetics program. RESULTS The main pharmacokinetic parameterswere of test and reference azithromycin granules were as follows: t1/2 were (44.7 ±15.2) h and(42.0 ±13.0) h; Tmax were (2.5 ±1.1) h and (2.6 ±1.7) h; Cmax were (574.6±209.2) ng·mL-1 and (594.5 ±229.9)ng·mL-1 ; AUC0-144 were(5 319.6±2 507.8) h·ng·mL-1 and (5 710.7±2 710.1) h·ng·mL-1; AUC0-∞ were(5 704.2±2 858.7) h·ng·mL-1 and(6 010.0±2 808.1) h·ng·mL-1. The relative bioavailability of tested to reference granules was (94.2±15.7)% according to AUC0-144. CONCLUSION The two formulations were bioequivalent.
Key words:  azithromycin granules  pharmacokinetic  bioequivalent  HPLC-MS/MS
扫一扫关注本刊微信